Navigation Links
GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Date:12/17/2007

Study Shows TYKERB Combination Reduced the Size of Brain Tumors Associated

with HER2-Positive Breast Cancer

SAN ANTONIO, Texas, Dec. 17 /PRNewswire/ -- GlaxoSmithKline announced today results from the extension arm of a Phase II study on its first-in-class, oral small molecule HER2 (ErbB2) kinase inhibitor, TYKERB(R) (lapatinib). In this study of 49 patients, the combination of TYKERB plus capecitabine (Xeloda(R)) showed a reduction in HER2-positive breast cancer that had spread to the brain and had progressed on TYKERB alone(1). Specifically, 20 percent of patients who received TYKERB plus capecitabine experienced at least a 50 percent volumetric reduction in measurable brain metastases; 37 percent of patients experienced a volumetric decrease that was greater than or equal to 20 percent. This is important because up to one-third of women with HER2-positive metastatic breast cancer may develop brain metastases during the course of their disease(2). Results of this and other important TYKERB studies are being presented at the 2007 San Antonio Breast Cancer Symposium in San Antonio, TX.

"As women live longer with advanced breast cancer, some are developing brain metastases that are getting worse despite standard treatments, such as radiation," said Nancy U. Lin, M.D., lead investigator and Instructor in Medicine, Dana-Farber Cancer Institute. "Very few medications have shown activity in the treatment of brain metastases, in particular HER2-positive metastatic breast cancer patients and therefore, these data are quite encouraging."

TYKERB, in combination with capecitabine, is approved in the United States for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane and trastuzumab (Herceptin(R))(3). Additional studies are underway to learn the full potential of TYKERB for the prevention and treatment of brai
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
3. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
6. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
7. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Once ... to provide a larger packaged waste water treatment plant ... King Abdullah Economic City (KAEC). Two years ago Bioshaft ... Jeddah Gate Development, serving two residential towers with an ... is over a quarter million gallons per day and ...
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... promotions as well as changes to Martine Rothblatt ... Promotions United Therapeutics announced the promotion ... Co-Chief Executive Officer and David Zaccardelli , Pharm.D. ... connection with these promotions, Dr. Rothblatt,s title will change ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... LEXINGTON, Mass., Sept. 29 RainDance,Technologies announced ... a,research initiative conducted with sanofi-aventis, Paris (EURONEXT: ... of Strasbourg, France, to develop,the next generation ... The consortium was founded with the assistance ...
... Sept. 29 diaDexus, Inc.,today announced its partnership ... dedicated to combating cardiovascular disease in,current and retired ... as part,of the LHF,s cardiovascular risk assessment and ... risk for suffering a heart,attack or stroke., ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... chairman and CEO,will present at the JMP Securities Healthcare ... Time at Le Parker Meridien in New York., ... discussion,of the development of picoplatin, the Company,s lead product ...
Cached Biology Technology:RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 2RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 3RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 4RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster 5diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players 2Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference 2
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... -- According to a new market research ... Access Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), ... Geography - Global Forecasts to 2020", published by MarketsandMarkets, ... around $25 Billion in 2014 and is expected to ... of 8.69%. Browse 116 market data Tables ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... November 13, 2012Following an infection, dysregulation of the immune ... an often fatal condition called severe sepsis or septic ... underlying immune dysfunction remain poorly understood. Regulatory T cells ... to have an important role in suppressing the immune ...
... some glaciers of the Himalayas will continue shrinking for ... Young University geology professor Summer Rupper comes after her ... the monsoonal Himalayas. Published in Geophysical Research Letters ... climate remained steady, almost 10 percent of Bhutan,s glaciers ...
... PHILADELPHIA Passing one,s genes on to the next generation ... that the body would work to ensure that the genes ... New research by biologists at the University of ... the body does exactly that. This protective role is fulfilled ...
Cached Biology News:Are we closer to understanding the cause of deadly sepsis? 2Himalayan glaciers will shrink even if temperatures hold steady 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 2A class of RNA molecules protects germ cells from damage, Penn vet researchers show 3
...
... kit allows for rapid, convenient, and efficient ... bind/wash/elute process utilizes a spin column to ... for concentration of proteins which were electro-eluted ... strong ion exchangers, offering high binding capacity ...
... techniques, the AutoTrace SPE is a powerful, high-throughput workstation dedicated specifically for automating ... elution steps for large volumes aqueous solution extractions (up to 2000ml's). ... ... ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
Biology Products: